Sangrix Inc. filed an amended proxy statement proposing an 8-for-1 reverse share consolidation of its Class A and Class B ordinary shares to maintain Nasdaq listing compliance. The transaction would reduce authorized capital from 200 billion to 25 billion shares, with a new effective date of November 13, 2026. Sangrix Inc. is a biotechnology company.
